MK-2214 study: To slow changes due to Alzheimer's disease.
The MK-2214 study by Merck is designed to evaluate if MK-2214, an investigational drug, can slow down changes in the brain linked to Alzheimer's disease in people at an early stage. MK-2214 is investigational and has not been approved by the FDA.
Eligibility Criteria
Study goal and designLimiting the spread of tau protein in early Alzheimer's disease
The study is focused on whether MK-2214 can help slow Alzheimer's disease at an early stage by targeting tau. By limiting the spread of tau, researchers hope the treatment may slow down the progression of memory loss and other symptoms of the disease.
Study-related care and supportComprehensive medical oversight and support
While contributing to research, participants receive:
- The possibility to receive the investigation study drug
- Regular brain scans and memory assessments
- Study visits with qualified medical professionals
All medical and travel costs related to the study are covered.
Volunteer journeyA structured research experience
1 - Express your interest: Answer a questionnaire to check preliminary criteria.
2 - Meet the study team: Complete a detailed brain and memory evaluation.
3 - Begin treatment (or placebo): Receive MK-2214 or placebo by Intravenous IV infusion every 4 weeks for up to 2 years.
4 - Continue the study : Be monitored during follow-up visits, and get health check-ups to observe any changes in cognition.
Join the Merck study
Contribute to progress, support research, help others, and care for your health.
Participate in the study